Related Experiment Video
Updated: Dec 16, 2025
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Targeting the medulloblastoma: a molecular-based approach
Sabino Luzzi1, Alice Giotta Lucifero2, Ilaria Brambilla3
1Neurosurgery Unit, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Neurosurgery Unit, Department of Surgical Sciences, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. sabino.luzzi@unipv.it.
Background:
The lack of success of standard therapies for medulloblastoma has highlighted the need to plan a new therapeutic approach. The purpose of this article is to provide an overview of the novel treatment strategies based on the molecular characterization and risk categories of the medulloblastoma, also focusing on up-to-date relevant clinical trials and the challenges in translating tailored approaches into clinical practice.
Methods:
An online search of the literature was carried out on the PubMed/MEDLINE and ClinicalTrials.gov websites about molecular classification of medulloblastomas, ongoing clinical trials and new treatment strategies. Only articles in the English language and published in the last five years were selected. The research was refined based on the best match and relevance.
Results:
A total 58 articles and 51 clinical trials were analyzed. Trials were of phase I, II, and I/II in 55%, 33% and 12% of the cases, respectively. Target and adoptive immunotherapies were the treatment strategies for newly diagnosed and recurrent medulloblastoma in 71% and 29% of the cases, respectively.
Conclusion:
Efforts are focused on the fine-tuning of target therapies and immunotherapies, including agents directed to specific pathways, engineered T-cells and oncoviruses. The blood-brain barrier, chemoresistance, the tumor microenvironment and cancer stem cells are the main translational challenges to be overcome in order to optimize medulloblastoma treatment, reduce the long-term morbidity and increase the overall survival.
Insights
New medulloblastoma treatments focus on molecular subtypes and immunotherapies. Overcoming challenges like the blood-brain barrier is key to improving survival and reducing side effects.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Standard medulloblastoma therapies show limited success, necessitating novel treatment strategies.
- Molecular characterization and risk stratification are crucial for developing personalized therapeutic approaches.
Purpose of the Study:
- To provide an overview of novel treatment strategies for medulloblastoma.
- To highlight current clinical trials and challenges in translating tailored approaches into practice.
Main Methods:
- Literature search on PubMed/MEDLINE and ClinicalTrials.gov for molecular classification, clinical trials, and new treatment strategies.
- Selection of English-language articles published within the last five years.
Main Results:
- Analysis of 58 articles and 51 clinical trials (Phase I, II, I/II).
- Target and adoptive immunotherapies represent key strategies for both newly diagnosed and recurrent medulloblastoma.
Conclusions:
- Ongoing efforts focus on refining targeted therapies and immunotherapies, including engineered T-cells and oncoviruses.
- Key translational challenges include the blood-brain barrier, chemoresistance, tumor microenvironment, and cancer stem cells, which must be addressed to improve outcomes.
